Results 141 to 150 of about 784,460 (315)

379. Analysis of tumor marker (CA15-3, CEA) on breast cancer patient with bone metastasis (scintigram)

, 1990
Toshihide Ise, Eiichiroh Nemoto, Atsushi Seto, Takatoshi Okumura   +3 more
openalex   +2 more sources

Not easy to become a tumor marker [PDF]

, 2016
Bogdan Solnica
openalex   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Clinical Utility of the Apolipoprotein A2 Isoform Index as a Tumor Marker for Pancreatic Cancer. [PDF]

JGH Open
Hoshino T, Mizuide M, Suzuki Y, Yasuoka H, Naganuma A, Hatanaka T, Kakizaki S, Ryozawa S.   +7 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

From Tumor Marker to Congestion Indicator: The Expanding Role of CA-125 in Heart Failure and Beyond. [PDF]

Health Sci Rep
Almasi MH, Salehi SA, Ebrahimi A, Heidaresfahani L, Nassiri A.   +4 more
europepmc   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

A Comparative Study of the Clinical Laboratory Quality Control Performance of AI-PBRTQC and Traditional PBRTQC Model in Tumor Marker Testing. [PDF]

Diagnostics (Basel)
Su B, Zhang Y, Wu X, Jiang Y, Song Y, Shi X.   +5 more
europepmc   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Anti-Thyroglobulin Antibodies as a Surrogate Tumor Marker for the Follow-Up of the Differentiated Thyroid Carcinoma: Clinical Implications and Pitfalls. [PDF]

Balkan Med J
Eraslan Aydemir E, Özkara Akkuş F, Erdoğan MF.   +2 more
europepmc   +1 more source